Mayne Pharma opens $80mn manufacturing facility in North Carolina
The Australian pharmaceutical company, Mayne Pharma, has opened its US$80mn manufacturing facility in North Carolina.
The site will be used to produce oral solid-dose medication and will quadruple the firm’s capacity in the US.
The 126,000sqft facility will bring Mayne Pharma’s oral solid-dose capacity to 1bn doses in the country.
The new sit will also offer new capacity to manufacture potent compounds and modifies-releasse bead/pellet products.
SEE ALSO:
-
Amgen chooses Rhode Island for its new next generation biomanufacturing plant
-
Terumo Corporation to invest £33mn into its subsidiary, Vascutek Limited
The firm will now work on commercial-scale, solvent capable, fluid-bed processing and film coating for the first time in the US.
“This new Greenville facility will greatly enhance our internal capacity and capability to support the mid- to long-term growth potential we see for our business and allows us to manufacture in the United States advanced drug-delivery technologies that until today were only available in our Australian facility,” commented Scott Richards, CEO of Mayne Pharma.
“The new plant will enable us to better control our supply chain, serve our customers better and reduce product costs.”
“In the next few years, Mayne Pharma expects to introduce more than 20 products and double its manufacturing volumes in the Greenville site, driven by the pipeline of products under development, the transfer in-house of several products currently manufactured by third parties, and by providing our Metrics Contract Services clients with commercial contract manufacturing services.”
